Proteomics receives $1.1 million in R&D tax incentive
Filed with ASX · · 1 page · English
Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a pioneer in predictive diagnostics, is pleased to announce that its cash reserves have been further strengthened by the receipt of $1.1 million in research and development tax incentive for the 2019-20 financial year. This follows the recent successful placement of $6m [ASX: 23 October; 2 November]. Proteomics Interna
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- Completion of Placement and Appendix 2A
- September 2020 Quarterly Activities Report and Appendix 4C
- Proteomics International raises $6m in successful Placement
- First distribution agreement for PromarkerD immunoassay
- Partnership with QIMR Berghofer targets oesophageal cancer
Later from Proteomics International Laboratories
- PromarkerD clinical assay performance results published
- Middle East is next market for PromarkerD immunoassay test
- AGM Investor Presentation
- December 2020 Quarterly Activities Report and Appendix 4C
- Proteomics International seeks FDA approval for PromarkerD
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories